SCHEMBL6864809

SCHEMBL6864809

O=C1CCN(c2ccc(/C=C3/SC(N4CCOCC4)=NC3=O)cc2)CC1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 5/20 0.61
KMT2A Q03164 5/20 0.61
GRIN1 Q05586 1/20 0.60
GRIN2B Q13224 1/20 0.60
DCTPP1 Q9H773 1/20 0.60
ALOX5 P09917 2/20 0.59
ALDH1A1 P00352 6/20 0.59
CYP1A2 P05177 2/20 0.59
CYP2C19 P33261 2/20 0.59
MAPT P10636 6/20 0.59
KDM4E B2RXH2 1/20 0.59
GAA P10253 1/20 0.59
HTT P42858 1/20 0.56
RAB9A P51151 4/20 0.56
SMN1; SMN2 Q16637 2/20 0.56
NPSR1 Q6W5P4 2/20 0.56
HPGD P15428 1/20 0.56
NPC1 O15118 3/20 0.54
MAPK1 P28482 1/20 0.53
IDE P14735 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6864814 1.00 MEN1 (0.61) MEN1KMT2AGRIN1GRIN2BDCTPP1
SCHEMBL6870971 0.89 RAB9A (0.70) MEN1KMT2AGRIN1GRIN2BDCTPP1
SCHEMBL6870969 0.89 RAB9A (0.70) MEN1KMT2AGRIN1GRIN2BDCTPP1
SCHEMBL6865646 0.87 ENPP2 (0.67) MEN1KMT2AGRIN1GRIN2BDCTPP1
SCHEMBL6865640 0.87 ENPP2 (0.67) MEN1KMT2AGRIN1GRIN2BDCTPP1
SCHEMBL6876895 0.84 MEN1 (0.57) MEN1KMT2AGRIN1GRIN2BDCTPP1
SCHEMBL6876887 0.84 MEN1 (0.57) MEN1KMT2AGRIN1GRIN2BDCTPP1
SCHEMBL4358730 0.84 MEN1 (0.65) MEN1KMT2AGRIN1GRIN2BDCTPP1
SCHEMBL4362311 0.84 ENPP2 (0.69) MEN1KMT2ADCTPP1ALDH1A1CYP1A2
SCHEMBL4357214 0.84 KMT2A (0.65) MEN1KMT2AGRIN1GRIN2BDCTPP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6821991-B2 FOR THERAPY OF METABOLIC DISORDERS RELATED TO INSULIN RESISTANCE OR HYPERGLYCEMIA (ASSOCIATED WITH OBESITY OR GLUCOSE INTOLERANCE), ATHEROSCLEROSIS, GASTROINTESTINAL DISORDERS, NEUROGENETIC INFLAMMATION, FREQUENT URINATION WYETH 2004-11-23 US disclosed
US-20030176412-A1 2-substituted thiazolidinones as beta-3 adrenergic receptor agonists WYETH 2003-09-18 US disclosed
US-6583140-B2 Useful in treating or inhibiting metabolic disorders related to insulin resistance or hyperglycemia, atherosclerosis, gastrointestinal disorders WYETH 2003-06-24 US disclosed
US-20020169325-A1 2-substituted thiazolidinones as beta-3 adrenergic receptor agonists WYETH 2002-11-14 US disclosed
US-6410734-B1 INSULIN RESISTANCE; HYPOGLYCEMIC AGENTS; ANTICHOLESTEROL AGENTS; GASTROINTESTINAL DISORDERS WYETH 2002-06-25 US disclosed
WO-2002006281-A1 2-SUBSTITUTED THIAZOLIDINONES AS BETA-3 ADRENERGIC RECEPTOR AGONISTS WYETH (US) 2002-01-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020169325-A1 2-substituted thiazolidinones as beta-3 adrenergic receptor agonists ADRB1, ADRB3, ADRB2 MEN1 3320/4885KMT2A 3512/4885GRIN1 1147/4885
US-20030176412-A1 2-substituted thiazolidinones as beta-3 adrenergic receptor agonists ADRB1, ADRB3, ADRB2 MEN1 3320/4885KMT2A 3512/4885GRIN1 1147/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.